Tegio has anti-tumor effects and is mainly used for unresectable locally advanced or metastatic gastric cancer. Common side effects of monotherapy include skin pigmentation, anemia, decreased hemoglobin, lymphopenia, neutropenia, leukopenia, leukocytosis, elevated ALP, hypokalemia, elevated creatine kinase, diarrhea, enterocolitis, vomiting, decreased appetite, and extremity edema. Important adverse effects of Tegio include myelosuppression, hemolytic anemia, disseminated intravascular coagulation, fulminant hepatitis, dehydration, severe enteritis, interstitial pneumonitis, myocardial infarction, angina pectoris, severe stomatitis, peptic ulcers, hemorrhage or perforation, cerebral leukoencephalopathy, rhabdomyolysis, and loss of sense of smell. Tigio common preparation for capsules, the use of drugs need to pay attention to, allergic to Tigio is prohibited, severe myelosuppression, severe hepatic and renal function abnormalities in patients is prohibited, is receiving other fluorouracil antineoplastic drugs, flucytosine, solifudine and its structural analogues of the treatment of patients is prohibited, known or likely to be pregnant women is prohibited, the use of drugs in children is not clear, the elderly use with caution. If you need to use Tigio, it is recommended to consult a professional doctor and follow the doctor’s instructions to standardize the treatment, not to blindly use the drug on their own.